Nicholas Latchana1, Mallory J DiVincenzo2, Kelly Regan3,4, Zachary Abrams4, Xiaoli Zhang4, Naduparambil K Jacob5, Alejandro A Gru6, Paolo Fadda7, Joseph Markowitz8, J Harrison Howard9, William E Carson9. 1. Department of General Surgery, University of Toronto, Toronto, Canada. 2. Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio. 3. Medical Scientist Training Program and Biomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio. 4. Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio. 5. Department of Radiation Oncology, The Ohio State University, Columbus, Ohio. 6. Department of Pathology, University of Virginia, Charlottesville, Virginia. 7. Department of Molecular Virology, Immunology and Medical Genetics, The Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, The Ohio State University, Columbus, Ohio. 8. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida. 9. Department of Surgery, The Ohio State University, Columbus, Ohio.
Abstract
BACKGROUND AND OBJECTIVES: MicroRNAs (miRs) are noncoding RNAs that regulate protein translation and melanoma progression. Changes in plasma miR expression following surgical resection of metastatic melanoma are under-investigated. We hypothesize differences in miR expression exist following complete surgical resection of metastatic melanoma. METHODS: Blood collection pre- and post-surgical resection was performed in six individuals with solitary melanoma metastases. miR expression in extracted RNA was quantified using the NanoString nCounter Digital Analyzer. RESULTS: Pre- and post-surgical plasma samples contained 216 miRs with expression above baseline. Comparison of postsurgical to preresection samples revealed differential expression of 25 miRs: miR-let-7a, miR-let7g, miR-15a, miR-16, miR-22, miR-30b, miR-126, miR-140, miR-145, miR-148a, miR-150-5p, miR-191, miR-378i, miR-449c, miR-494, miR-513b, miR-548aa, miR-571, miR-587, miR-891b, miR-1260a, miR 1268a, miR-1976, miR-4268, miR-4454 (P < 0.05). Utilizing P < 0.0046 as a cutoff to control for one false positive among the 216 miRs revealed that postsurgical melanoma plasma samples had upregulation of miR-1260a (P = 0.0007) and downregulation of miR-150-5p (P = 0.0026) relative to pre-surgical samples. CONCLUSIONS: Differential expression of miR-150-5p and miR-1260a is present in plasma following surgical resection of metastatic melanoma in this small sample (n = 6) of melanoma patients. Therefore, further investigation of these plasma miRs as noninvasive biomarkers for melanoma is warranted.
BACKGROUND AND OBJECTIVES: MicroRNAs (miRs) are noncoding RNAs that regulate protein translation and melanoma progression. Changes in plasma miR expression following surgical resection of metastatic melanoma are under-investigated. We hypothesize differences in miR expression exist following complete surgical resection of metastatic melanoma. METHODS: Blood collection pre- and post-surgical resection was performed in six individuals with solitary melanoma metastases. miR expression in extracted RNA was quantified using the NanoString nCounter Digital Analyzer. RESULTS: Pre- and post-surgical plasma samples contained 216 miRs with expression above baseline. Comparison of postsurgical to preresection samples revealed differential expression of 25 miRs: miR-let-7a, miR-let7g, miR-15a, miR-16, miR-22, miR-30b, miR-126, miR-140, miR-145, miR-148a, miR-150-5p, miR-191, miR-378i, miR-449c, miR-494, miR-513b, miR-548aa, miR-571, miR-587, miR-891b, miR-1260a, miR 1268a, miR-1976, miR-4268, miR-4454 (P < 0.05). Utilizing P < 0.0046 as a cutoff to control for one false positive among the 216 miRs revealed that postsurgical melanoma plasma samples had upregulation of miR-1260a (P = 0.0007) and downregulation of miR-150-5p (P = 0.0026) relative to pre-surgical samples. CONCLUSIONS: Differential expression of miR-150-5p and miR-1260a is present in plasma following surgical resection of metastatic melanoma in this small sample (n = 6) of melanomapatients. Therefore, further investigation of these plasma miRs as noninvasive biomarkers for melanoma is warranted.
Authors: Weixin Wang; Meghan Corrigan-Cummins; Justin Hudson; Irina Maric; Olga Simakova; Sattva S Neelapu; Larry W Kwak; John E Janik; Barry Gause; Elaine S Jaffe; Katherine R Calvo Journal: Haematologica Date: 2011-11-18 Impact factor: 9.941
Authors: Varsha Tembe; Sarah-Jane Schramm; Mitchell S Stark; Ellis Patrick; Vivek Jayaswal; Yue Hang Tang; Andrew Barbour; Nicholas K Hayward; John F Thompson; Richard A Scolyer; Yee Hwa Yang; Graham J Mann Journal: Pigment Cell Melanoma Res Date: 2015-01-05 Impact factor: 4.693
Authors: Vasily N Aushev; Irina B Zborovskaya; Konstantin K Laktionov; Nicolas Girard; Marie-Pierre Cros; Zdenko Herceg; Vladimir Krutovskikh Journal: PLoS One Date: 2013-10-09 Impact factor: 3.240
Authors: So-Woon Kim; Young Il Kim; Bilal Mustafa; Mi-Ju Kim; Gowun Jeong; Sung-Min Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seung-Mo Hong; In Ja Park Journal: Mod Pathol Date: 2020-07-24 Impact factor: 7.842
Authors: Iwona Nowak; Elżbieta Boratyn; Sebastian Student; Stephan F Bernhart; Jörg Fallmann; Małgorzata Durbas; Peter F Stadler; Hanna Rokita Journal: RNA Biol Date: 2020-08-20 Impact factor: 4.652